Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.
You may also be interested in...
Wyeth’s Viviant “Approvable” For Osteoporosis
Analysis sought for treatment indication is similar to what FDA requested for prevention setting.
Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
Selective estrogen receptor modulator now is called Fablyn rather than Oporia, a name under which it received two “not approvable” letters.
Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis
Firm continues to plan an additional submission this year for an osteoporosis treatment claim.